Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFICA Phase 3
2020-000111-69Phase 3Active
- Sponsor
- CTI BioPharma Corp.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pacritinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more (2 arms), sponsored by CTI BioPharma Corp. Primary endpoint: Spleen volume reduction response rate at Week 24. Started Apr 2020; status: active.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2020-000111-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000111-69.